Gritstone Presents on Phase 1 Studies Evaluating Next-Generation Vaccine Candidate for COVID-19

 Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced results from all three (3) Phase 1 studies evaluating its self-amplifying mRNA (samRNA) vaccine candidates against COVID-19 (part of the company’s CORAL program) are to be presented at IDWeek 2023, occurring October 11-15, 2023, in Boston, MA. Last week, Gritstone bio announced a contract with the Biomedical Advanced Research and Development Authority (BARDA) to advance the program into a 10,000 patient, randomized Phase 2b comparative study against COVID-19. The agreement was awarded as part of ‘Project NextGen,’ an initiative by the U.S. Department of Health and Human Services (HHS) to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19.

Copies of the presentations will be posted on the Events page of the Gritstone bio website after their conclusion.

https://www.globenewswire.com/news-release/2023/10/04/2754942/0/en/Gritstone-bio-Announces-Presentations-from-Phase-1-Studies-Evaluating-Next-Generation-Vaccine-Candidate-for-COVID-19-at-IDWeek-2023.html